effects-on-rna-quality-pbmcs-under-different-cryopreservation-times

Effects on RNA Quality of PBMCs Under Different Cryopreservation Times and Processing Methods in Patients with Advanced Non-Small Cell Lung Cancer

Cryopreserved peripheral blood mononuclear cells (PBMCs) are widely used in RNA sequencing (RNA-seq), and the quality of their RNA directly influences ...

Jilin Cancer Hospital

In this study, we aimed to investigate the associations of three single-nucleotide polymorphisms (SNPs) on TITF1/TITF2 (rs944289, rs965513, and rs1443434) with susceptibility to papillary thyroid carcinoma (PTC) and with nodular goiter (NG) in northern Chinese Han populations.

Association of rs944289, rs965513, and rs1443434 in TITF1/TITF2 with Risks of Papillary Thyroid Carcinoma and with Nodular Goiter in Northern Chinese Han Populations.

Relapse and drug resistance are the main causes of mortality in patients with small‑cell lung cancer (SCLC). Intratumoral heterogeneity (ITH) is a key biological mechanism that leads to relapse and drug resistance. Phenotypic plasticity is an important factor that leads to ITH in SCLC, although its mechanisms and key regulatory factors remain to be elucidated. In the present study, cell proliferation and cell switch assay were measured using trypan blue. Alamar Blue was used to test drug sensitivity. Differential genes were screened by RNA sequencing. Reverse transcription‑quantitative PCR and western blotting were performed to assess the expressions of CSF2/p‑STAT3/MYC pathway related molecules, neuroendocrine (NE)/non‑neuroendocrine (non‑NE), transcription factors and drug‑related targets. The present study found that SCLC cell line NCI‑H69 exhibited adherent (H69A) and suspensive (H69S) phenotypes, which could switch back and forth. The two phenotypic cells had significant differences in cellular NE and non‑NE characteristics, drug sensitivity and expression of drug‑related targets. RNA sequencing showed that granulocyte‑macrophage colony‑stimulating factor [i.e., colony‑stimulating factor 2 (CSF2)] was the main differentially expressed gene between the two phenotypes and that H69A cells highly expressed CSF2. The inhibition of CSF2 promoted the transformation from H69A to H69S, increased drug sensitivity and NE marker expression and decreased the non‑NE marker expression in H69A. The STRING, Pathway Commons and Reactome databases showed a potential regulatory relationship between CSF2 and phosphorylated signal transducer and activator of transcription 3 (p‑STAT3)/MYC. p‑STAT3 and MYC expression was higher in H69A cells than in H69S cells and CSF2 silencing inhibited their expression. Taken together, these results indicated that CSF2 may regulate the phenotypic plasticity of SCLC through the phosphorylated STAT3/MYC pathway, thereby limiting the transformation between cell clones with different phenotypes and changing the sensitivity of specific cell clones to targeted drugs. Targeting CSF2 may be a potential therapeutic strategy to overcome drug resistance in SCLC treatment by influencing ITH.

Colony‑stimulating factor CSF2 mediates the phenotypic plasticity of small‑cell lung cancer by regulating the p‑STAT3/MYC pathway.

Lung adenocarcinoma (LUAD) is the most common pathological type of lung cancer. In recent years, immunotherapy has greatly changed the treatment pattern of advanced LUAD. However, only a small proportion of LUAD patients benefitted from immune checkpoint inhibitor therapy. There is an urgent need to develop a biomarker to predict immune therapy response. E2F7 has been shown to be closely related to immune cell infiltration and immune checkpoint expression in tumors. However, it is unclear whether the E2F7 expression is related to the immunotherapy efficacy in LUAD. Therefore, we conducted this study to investigate the clinical characteristics, function, and immunotherapy responsiveness of E2F7 expression, and to explore the potential of E2F7 as an immunotherapy response biomarker in LUAD. We analyzed the clinical characteristics and biological function of E2F7 expression based on data from the Cancer Genome Atlas and Gene Expression Omnibus database. In addition, we used single-cell sequencing data to analyze the immune regulatory effects of E2F7 in LUAD. Furthermore, we analyzed the immunotherapy response prediction ability of E2F7 expression based on the immunotherapy database. Compared to normal lung tissue, E2F7 was specifically overexpressed in LUAD, and its expression was associated with higher malignancy and poor efficacy. E2F7 high expression was an independent risk factor affecting the prognosis of LUAD. E2F7 was enriched in cell division and cell cycle functions. In addition, the expressions of immune checkpoints were correlated with the E2F7 expression. E2F7 was highly expressed in myeloid cells, and E2F7 highly expressed myeloid cells were associated with immune and inflammatory responses. Moreover, the expression level of E2F7 can effectively distinguish different immune therapy responses in LUAD patients. E2F7 was upregulated in LUAD, and high expression of E2F7 was associated with higher malignancy and poor efficacy. E2F7 high expression was an independent risk factor affecting the prognosis of LUAD. Moreover, E2F7 may exert its immunosuppressive effect by affecting the function of myeloid cells. These results indicated the potential role of E2F7 as a biomarker for predicting LUAD immunotherapy responses.

The predictive value of E2F7 in immunotherapy efficacy for lung adenocarcinoma: An observational study.

Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha   mutations are associated with drug resistance and prognosis in lung cancer; however, the consistency and clinical value of  mutations between tissue and liquid samples are unknown.

Highly consistency of  mutation spectrum between circulating tumor DNA and paired tissue in lung cancer patients.

Depression substantially impacts on quality of life, personal relationships, and self-care. Gastrointestinal disorders are the common comorbidity of depression and 24.3% of patients with depression have disordered bowel habits. Dietary intake of live microbes alters the host's microflora and is beneficial for the prevention and control of bowel health and depression. We aim to investigate the association of dietary intake of live microbes with bowel health and depression and to further examine weather bowel health or depression mediates the therapeutic effect of live microbes.

Association of dietary intake of live microbes with bowel health and depression in US adults: a cross-sectional study of NHANES 2005-2010.

Small cell lung cancer (SCLC) is acknowledged as the most aggressive histological subtype among the various types of lung cancer. Among patients with advanced-stage SCLC, liver metastasis (LM) is frequently observed and is associated with the most unfavorable prognosis. The purpose of the present study is to investigate the synchronous metastatic sites in SCLC patients with LM, and to construct a nomogram for predicting the survival of these patients.

Metastatic sites, prognosis, and a new nomogram for predicting overall survival among small cell lung cancer patients with liver metastasis: a retrospective study based on SEER.

The KRAS mutation represents the most prevalent oncogenic alteration observed in human cancers. Its primary role involves directly driving malignant tumor development and growth through the activation of downstream signaling pathways. Increasing evidence suggests that KRAS significantly affects the immune response of KRAS-mutant tumors by modulating immune-related signaling and inflammatory pathways. In addition to broadly regulating the KRAS-associated immune signaling, KRAS influences immune cell phenotype and function by triggering tumor metabolic pathways. Here, we reviewed the KRAS mutation-associated immune microenvironment features and discussed how KRAS remodels the immune microenvironment by regulating immune-related molecules, inflammatory factors, and multiple metabolic pathways, offering insights that could be useful for developing effective immune-responsive therapies for KRAS-mutant tumors.

Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming.

The treatment of patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) whose disease progresses after tyrosine-kinase inhibitors (TKIs) treatment has become a research hotspot.

Efficacy and safety analysis of treatment in patients with EGFR-mutated advanced NSCLC who progressed on TKIs: a systematic review and meta-analysis.

To investigate the clinical characteristics and impact of  mutations in patients with non-small cell lung cancer (NSCLC).

Article	Year
Association of rs944289, rs965513, and rs1443434 in TITF1/TITF2 with Risks of Papillary Thyroid Carcinoma and with Nodular Goiter in Northern Chinese Han Populations. International journal of endocrinology\| PubMed ID: 32104174	2020
Colony‑stimulating factor CSF2 mediates the phenotypic plasticity of small‑cell lung cancer by regulating the p‑STAT3/MYC pathway. Oncology reports\| PubMed ID: 35583004	2022
The predictive value of E2F7 in immunotherapy efficacy for lung adenocarcinoma: An observational study. Medicine\| PubMed ID: 38905387	2024
Highly consistency of mutation spectrum between circulating tumor DNA and paired tissue in lung cancer patients. Heliyon\| PubMed ID: 39071569	2024
Association of dietary intake of live microbes with bowel health and depression in US adults: a cross-sectional study of NHANES 2005-2010. Environmental health and preventive medicine\| PubMed ID: 39756916	2024
Metastatic sites, prognosis, and a new nomogram for predicting overall survival among small cell lung cancer patients with liver metastasis: a retrospective study based on SEER. Journal of thoracic disease\| PubMed ID: 39975725	2025
Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming. Cell death & disease\| PubMed ID: 41184283	2025
Efficacy and safety analysis of treatment in patients with EGFR-mutated advanced NSCLC who progressed on TKIs: a systematic review and meta-analysis. Frontiers in immunology\| PubMed ID: 41229435	2025
Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring mutations. Annals of medicine\| PubMed ID: 41593906	2026

Heran Cui

Biography

JoVE Journal Publications

Other Publications